Buscar
Mostrando ítems 21-30 de 36
Preclinical assessment of the efficacy of a new antivenom (EchiTAb-Plus-ICP) for the treatment of viper envenoming in sub-Saharan Africa
(2010-02)
A preclinical assessment was performed on the neutralizing efficacy of a whole IgG polyspecific antivenom (EchiTAb-Plus-ICP®), designed for the treatment of snakebite envenomings in Nigeria. It was generated by immunizing ...
Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration
(2008)
The presence of human heterophilic antibodies against horse immunoglobulins
(HHA-HI) was determined by ELISA in sera from healthy volunteers and from patients who
received equine antivenom for therapy of snake bite ...
Proteomic and toxinological characterization of the venom of the South African Ringhals cobra Hemachatus haemachatus
(2018-06)
The protein composition and toxinological profile of the venom of the African spitting elapid Hemachatus haemachatus
(Ringhals) were characterized by bottom-up proteomics and functional in vitro and in vivo assays.
Venom ...
Impact of Regional Variation in Bothrops asper Snake Venom on the Design of Antivenoms: Integrating Antivenomics and Neutralization Approaches
(2010-10-21)
Intraspecific snake venom variations have implications in the preparation of venom pools for the generation of antivenoms. The impact of such variation in the cross-reactivity of antivenoms against Bothrops asper venom was ...
Antivenomic Characterization of Two Antivenoms Against the Venom of the Taipan, Oxyuranus scutellatus, from Papua New Guinea and Australia
(2014-11-05)
Antivenoms manufactured by bioCSL Limited (Australia) and Instituto Clodomiro Picado (Costa Rica) against the venom of the taipan snakes (Oxyuranus scutellatus) from Australia and Papua New Guinea (PNG), respectively, were ...
Antivenomic Assessment of the Immunological Reactivity of EchiTAb-Plus-ICP, an Antivenom for the Treatment of Snakebite Envenoming in Sub-Saharan Africa
(2010)
The immunoreactivity of EchiTAb-Plus-ICP, an antivenom developed for the treatment of snakebite envenoming in sub-Saharan Africa, to venoms of seven Echis and Bitis species, was assessed by “antivenomics.” This proteomic ...
Role of the animal model on the pharmacokinetics of equine-derived antivenoms
(2013-08)
Antivenom pharmacokinetics has been studied in heterologous models in which the animal species used as immunoglobulin source is different from that used as recipient. In these models, after intravenous administration of ...
Stability of equine IgG antivenoms obtained by caprylic acid precipitation: Towards a liquid formulation stable at tropical room temperature
(2009-05)
Liquid formulations of antivenom require a cold chain for their distribution and storage, especially in tropical countries characterized by high temperature and humidity (climatic zone IV). Since cold chain is often deficient ...
Purification of IgG and albumin from human plasma by aqueous two phase system fractionation
(2012-08)
The current shortages in human plasma products at global levels justify the development of new, cost effective plasma fractionation methods. We have developed a fractionation process to obtain immunoglobulin G (IgG) and ...
Study of the design and analytical properties of the lethality neutralization assay used to estimate antivenom potency against Bothrops asper snake venom
(2010-09)
The lethality neutralization assay performed in mice is the standard recommended by the World Health Organization to estimate antivenom potency. The interpretation of its results without considering its analytical capacity ...